IBIO Stock Overview
A preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
iBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.60 |
| 52 Week High | US$6.89 |
| 52 Week Low | US$1.05 |
| Beta | 1.3 |
| 1 Month Change | 50.54% |
| 3 Month Change | 102.90% |
| 1 Year Change | 374.58% |
| 3 Year Change | -96.84% |
| 5 Year Change | -99.30% |
| Change since IPO | -99.88% |
Recent News & Updates
Shareholder Returns
| IBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.9% | -0.8% | -3.4% |
| 1Y | 374.6% | -6.3% | 11.9% |
Return vs Industry: IBIO exceeded the US Biotechs industry which returned -6.3% over the past year.
Return vs Market: IBIO exceeded the US Market which returned 11.9% over the past year.
Price Volatility
| IBIO volatility | |
|---|---|
| IBIO Average Weekly Movement | 15.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: IBIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IBIO's weekly volatility has decreased from 31% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 16 | Martin Brenner | ibioinc.com |
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies.
iBio, Inc. Fundamentals Summary
| IBIO fundamental statistics | |
|---|---|
| Market cap | US$55.30m |
| Earnings (TTM) | -US$14.23m |
| Revenue (TTM) | US$375.00k |
147.5x
P/S Ratio-3.9x
P/E RatioIs IBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBIO income statement (TTM) | |
|---|---|
| Revenue | US$375.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$375.00k |
| Other Expenses | US$14.61m |
| Earnings | -US$14.23m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.44 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,795.73% |
| Debt/Equity Ratio | 10.7% |
How did IBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/09 01:51 |
| End of Day Share Price | 2025/03/07 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
iBio, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Keay Nakae | Chardan Capital Markets, LLC |